A
Aamir Malik
Chief U.S. Commercial Officer, Executive Vice President
All funds
crypto
Analyst signals
Portfolio activity and matriculation
Metrics use all recorded activity through 21 Jul 2026 across unknown. Later-round outcomes are capped at the period end.
100%companies with a later round · 1/1
1000000.00×median round-size step-up · n=1
Not availablemedian valuation step-up · n=0
0%recorded-solo rate · 0 solo / 1 syndicated
Science · 1 companies
These are activity signals, not fund-return metrics. Round capital is the full disclosed financing amount, not this fund's check size. “Recorded solo” means only one investor is present in the source data and is a lead signal, not verified lead status; syndicated rounds are a co-investor or follower signal. IRR, TVPI, DPI, ownership, exits, and market beta cannot be calculated from the available records.
People
Team
A
Alexandre de Germay
Chief International Commercial Officer, Executive Vice President
C
Chris Boshoff, MD, PhD
Chief Scientific Officer and President, Research & Development
C
Cyrus Taraporevala
Board Member
D
Dan R. Littman, M.D., Ph.D.
Board Member
D
Dave Denton
Chief Financial Officer and Executive Vice President
D
Dennis Hancock
Chief Information Officer, Executive Vice President
D
Doug Lankler
Chief Legal Officer, Executive Vice President
D
Dr. Albert Bourla
Chairman and Chief Executive Officer
J
James C. Smith
Board Member
J
James Quincey
Board Member
J
Joseph J. Echevarria
Board Member
L
Lindsay Havern
Head of Strategy, Executive Operations, Counsel to the CEO
M
Mike McDermott
Chief Global Supply and Quality Officer, Executive Vice President
M
Mortimer J. Buckley
Board Member
P
Payal Sahni Becher
Chief People Experience Officer, Executive Vice President
R
Ronald E. Blaylock
Board Member
S
Scott Gottlieb, M.D.
Board Member
S
Shantanu Narayen
Lead Independent Director
S
Susan Desmond-Hellmann, M.D., M.P.H
Board Member
S
Suzanne Nora Johnson
Board Member
Portfolio
Investments
Full financing histories for portfolio companies. Highlighted rounds are those where Pfizer Ventures is recorded as an investor.
VitaDAO
Science
VitaDAO is a decentralized autonomous organization focused on extending human healthspan and lifespan. It funds, governs, and supports early-stage longevity and biomedical research through community-owned intellectual-property tokens and decentralized governance.